---
title: "Dror Ortho-Design, Inc. 1Q 2026: Net income $(638,666), EPS $(0.00) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286315202.md"
description: "Dror Ortho-Design, Inc. reported a net loss of $(638,666) for Q1 2026, with diluted EPS of $(0.00). The company remains in the development stage with no material revenue. R&D spending decreased by 51% year-over-year. The company is preparing a new 510(k) submission for FDA clearance and aims to disrupt the aligner market with a smart aligner platform. Operations depend on raising additional capital for regulatory work and development. Following a share exchange in 2023, the company integrated a new management team for commercialization efforts."
datetime: "2026-05-13T20:41:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286315202.md)
  - [en](https://longbridge.com/en/news/286315202.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286315202.md)
---

# Dror Ortho-Design, Inc. 1Q 2026: Net income $(638,666), EPS $(0.00) — 10-Q Summary

Dror Ortho-Design, Inc. reported a net loss of $(638,666) for the first quarter of 2026, with diluted earnings per share of $(0.00). The company remains in the development stage and did not report material revenue for the quarter.

**Financial Highlights**

-   Net income was a loss of $(638,666) for Q1 2026, versus a loss of $(576,123) in Q1 2025.
-   Diluted EPS was $(0.00) for Q1 2026, unchanged from $(0.00) in the year‑ago quarter.
-   Revenue: Not reported for Q1 2026 (company remains in development stage with no material revenues).

**Business Highlights**

-   Product development and regulatory path: The company is preparing an updated Platform prototype and plans a new 510(k) submission to seek FDA clearance for expanded commercialization.
-   R&D shift: Research and development spending decreased 51% year over year as software development was reduced while work on intellectual property and prototypes continued.
-   Commercial strategy: Dror Ortho-Design is positioning a single smart aligner Platform that uses pulsating air for discreet at-home/night treatment aimed at disrupting the traditional aligner market.
-   Capital needs: Operations depend on raising additional capital to fund regulatory work, continued software and hardware development, and go-to-market activities.
-   Corporate transition: Following a 2023 share exchange, the company adopted Private Dror’s management team and integrated legacy board and officers to lead commercialization efforts.

Original SEC Filing: Dror Ortho-Design, Inc. \[ DROR \] - 10-Q - May. 13, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [DRTS.US](https://longbridge.com/en/quote/DRTS.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [LABD.US](https://longbridge.com/en/quote/LABD.US.md)

## Related News & Research

- [Alpha Tau Q1 Net Loss Expands; Plans Enrollment Completion In IMPACT Study In Q3,2026; Stock Up](https://longbridge.com/en/news/286879279.md)
- [Eton Secures U.S. IMPAVIDO Rights; $4.25M Fees, Up To $4M Milestones And 50-55% Revenue Share](https://longbridge.com/en/news/286966420.md)
- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 Ballot - SEC Filing](https://longbridge.com/en/news/286565204.md)
- [Skye Bioscience opens higher-dose Cohort 2 in nimacimab obesity Phase 2a study](https://longbridge.com/en/news/287053007.md)